1-17 of 17
Michael Untch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials

Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, Knut Engels, Christine Solbach, Kurt Diebold, Frederik Marmé, Volkmar Müller, Andreas Schneeweiss, Hans-Peter Sinn, Tanja Fehm, Christian Schem, Elmar Stickeler, Peter Fasching, Jan Budczies, Bärbel Felder, Valentina Nekljudova, Johannes Holtschmidt, Michael Untch, Carsten Denkert, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3868–3880.
https://doi.org/10.1158/1078-0432.CCR-24-0459
Published: 03 September 2024
View article titled, An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Open the PDF for An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials in another window
Includes: Supplementary data
Journal Articles

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

Theresa Link, Jens-Uwe Blohmer, Wolfgang D. Schmitt, Jan Dominik Kuhlmann, Marianne Just, Michael Untch, Oliver Stotzer, Peter A. Fasching, Marc Thill, Mattea Reinisch, Andreas Schneeweiss, Pauline Wimberger, Sabine Seiler, Jens Huober, Christian Jackisch, Kerstin Rhiem, Claus Hanusch, Bruno V. Sinn, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4606–4612.
https://doi.org/10.1158/1078-0432.CCR-23-1801
Published: 14 November 2023
View article titled, RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Open the PDF for RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial in another window
Includes: Supplementary data
Journal Articles

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

Terence M. Williams, Andreas Schneeweiss, Christian Jackisch, Changxian Shen, Karsten E. Weber, Peter A. Fasching, Carsten Denkert, Jenny Furlanetto, Ernst Heinmöller, Sabine Schmatloch, Thomas Karn, Christopher W. Szeto, Marion T. van Mackelenbergh, Valentina Nekljudova, Elmar Stickeler, Patrick Soon-Shiong, Christian Schem, Thomas Mairinger, Volkmar Müller, Frederik Marme, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3384–3394.
https://doi.org/10.1158/1078-0432.CCR-23-0362
Published: 01 September 2023
View article titled, Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Open the PDF for Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Peter A. Fasching, Christopher Szeto, Carsten Denkert, Stephen Benz, Karsten Weber, Patricia Spilman, Jan Budczies, Andreas Schneeweiss, Elmar Stickeler, Sabine Schmatloch, Christian Jackisch, Thomas Karn, Hans Peter Sinn, Mathias Warm, Marion van Mackelenbergh, Shahrooz Rabizadeh, Christian Schem, Ernst Heinmöller, Volkmar Mueller, Frederik Marmé, Patrick Soon-Shiong, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2456–2465.
https://doi.org/10.1158/1078-0432.CCR-22-2213
Published: 05 July 2023
View article titled, Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Open the PDF for Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1569–1581.
https://doi.org/10.1158/1078-0432.CCR-22-1989
Published: 14 April 2023
View article titled, Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Open the PDF for Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Bruno V. Sinn, Sibylle Loibl, Claus A. Hanusch, Dirk-Michael Zahm, Hans-Peter Sinn, Michael Untch, Karsten Weber, Thomas Karn, Clemens Becker, Frederik Marmé, Wolfgang D. Schmitt, Volkmar Müller, Christian Schem, Denise Treue, Elmar Stickeler, Frederik Klauschen, Nicole Burchardi, Jenny Furlanetto, Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2584–2591.
https://doi.org/10.1158/1078-0432.CCR-20-3113
Published: 01 May 2021
View article titled, Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Open the PDF for Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Thomas Karn, Tobias Meissner, Karsten E. Weber, Christine Solbach, Carsten Denkert, Knut Engels, Peter A. Fasching, Bruno V. Sinn, Iris Schrader, Jan Budczies, Frederik Marmé, Volkmar Müller, Uwe Holtrich, Bernd Gerber, Christian Schem, Brandon M. Young, Claus Hanusch, Elmar Stickeler, Jens Huober, Marion van Mackelenbergh, Brian Leyland-Jones, Tanja Fehm, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1896–1904.
https://doi.org/10.1158/1078-0432.CCR-19-1954
Published: 15 April 2020
View article titled, A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Open the PDF for A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial in another window
Includes: Supplementary data
Journal Articles

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial

Sibylle Loibl, Denise Treue, Jan Budczies, Karsten Weber, Albrecht Stenzinger, Wolfgang D. Schmitt, Wilko Weichert, Paul Jank, Jenny Furlanetto, Frederick Klauschen, Thomas Karn, Nicole Pfarr, Gunter von Minckwitz, Markus Möbs, Christian Jackisch, Christine Sers, Andreas Schneeweiss, Peter A. Fasching, Christian Schem, Michael Hummel, Marion van Mackelenbergh, Valentina Nekljudova, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3986–3995.
https://doi.org/10.1158/1078-0432.CCR-18-3258
Published: 01 July 2019
View article titled, Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Open the PDF for Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gunter von Minckwitz, Michael Untch, Klaus Pantel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5384–5393.
https://doi.org/10.1158/1078-0432.CCR-17-0255
Published: 14 September 2017
View article titled, Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Open the PDF for Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial in another window
Includes: Supplementary data
Journal Articles

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Barbara Ingold Heppner, Michael Untch, Carsten Denkert, Berit M. Pfitzner, Bianca Lederer, Wolfgang Schmitt, Holger Eidtmann, Peter A. Fasching, Hans Tesch, Christine Solbach, Mahdi Rezai, Dirk M. Zahm, Frank Holms, Manfred Glados, Petra Krabisch, Esther Heck, Angelika Ober, Petra Lorenz, Kurt Diebold, Jörg-Olaf Habeck, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5747–5754.
https://doi.org/10.1158/1078-0432.CCR-15-2338
Published: 30 November 2016
View article titled, Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Open the PDF for Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

Sibylle Loibl, Silvia Darb-Esfahani, Jens Huober, Alexander Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gunter von Minckwitz, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (11): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-15-0965
Published: 31 May 2016
View article titled, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)

Claus Hanusch, Andreas Schneeweiss, Sibylle Loibl, Michael Untch, Stefan Paepke, Sherko Kümmel, Christian Jackisch, Jens Huober, Jörn Hilfrich, Bernd Gerber, Holger Eidtmann, Carsten Denkert, Serban Costa, Jens Uwe Blohmer, Knut Engels, Nicole Burchardi, Gunter von Minckwitz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2924–2931.
https://doi.org/10.1158/1078-0432.CCR-14-2774
Published: 30 June 2015
View article titled, Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)
Open the PDF for Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) in another window
Journal Articles

Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

Sabine Riethdorf, Volkmar Müller, Liling Zhang, Thomas Rau, Sibylle Loibl, Martina Komor, Marc Roller, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Holger Eidtmann, Michael Untch, Gunter von Minckwitz, Klaus Pantel
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (9): 2634–2645.
https://doi.org/10.1158/1078-0432.CCR-09-2042
Published: 28 April 2010
View article titled, Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Open the PDF for Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert, Maja Heinrigs, Brigitte Rack, Alexander Marmé, Agnieszka Korfel, Michael Jäger, Horst Lindhofer, Harald Sommer, Eckhard Thiel, Michael Untch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3085–3091.
https://doi.org/10.1158/1078-0432.CCR-05-2436
Published: 17 May 2006
View article titled, Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer
Open the PDF for Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer in another window
Journal Articles

Association between HER-2/ neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

Gottfried E. Konecny, Y. Gloria Meng, Michael Untch, He-Jing Wang, Ingo Bauerfeind, Melinda Epstein, Petra Stieber, Jean-Michel Vernes, Johnny Gutierrez, Kyu Hong, Malgorzata Beryt, Hermann Hepp, Dennis J. Slamon, Mark D. Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (5): 1706–1716.
https://doi.org/10.1158/1078-0432.CCR-0951-3
Published: 10 March 2004
View article titled, Association between HER-2/ <em>neu</em> and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients
Open the PDF for Association between HER-2/ <em>neu</em> and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients in another window
Journal Articles

HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer

Gottfried Konecny, Michael Untch, Jane Arboleda, Cindy Wilson, Stephen Kahlert, Berit Boettcher, Margrit Felber, Malgorzota Beryt, Sandra Lude, Hermann Hepp, Dennis Slamon, Mark Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2448–2457.
Published: 01 August 2001
View article titled, HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer
Open the PDF for HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer in another window
Journal Articles

Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer

Gottfried Konecny, Michael Untch, Astrid Pihan, Rainer Kimmig, Martina Gropp, Petra Stieber, Herrmann Hepp, Dennis Slamon, Mark Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (6): 1743–1749.
Published: 01 June 2001
View article titled, Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer
Open the PDF for Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer in another window